Free Trial
NASDAQ:PDEX

Pro-Dex (PDEX) Stock Price, News & Analysis

Pro-Dex logo
$56.63 -2.64 (-4.45%)
Closing price 04:00 PM Eastern
Extended Trading
$56.76 +0.13 (+0.22%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Pro-Dex Stock (NASDAQ:PDEX)

Advanced

Key Stats

Today's Range
$56.51
$58.91
50-Day Range
$42.60
$58.50
52-Week Range
$23.47
$61.62
Volume
37,347 shs
Average Volume
26,126 shs
Market Capitalization
$180.82 million
P/E Ratio
15.64
Dividend Yield
N/A
Price Target
$56.00
Consensus Rating
Moderate Buy

Company Overview

Pro-Dex Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

PDEX MarketRank™: 

Pro-Dex scored higher than 28% of companies evaluated by MarketBeat, and ranked 729th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pro-Dex has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

  • Upside/Downside

    The consensus price target for Pro-Dex is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Pro-Dex has only been the subject of 1 research reports in the past 90 days.

  • Read more about Pro-Dex's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pro-Dex is 15.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.44.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pro-Dex is 15.93, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.71.

  • Price to Book Value per Share Ratio

    Pro-Dex has a P/B Ratio of 5.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Pro-Dex's valuation and earnings.
  • Percentage of Shares Shorted

    13.10% of the float of Pro-Dex has been sold short.
  • Short Interest Ratio / Days to Cover

    Pro-Dex has a short interest ratio ("days to cover") of 9.79.
  • Change versus previous month

    Short interest in Pro-Dex has recently decreased by 5.25%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Pro-Dex does not currently pay a dividend.

  • Dividend Growth

    Pro-Dex does not have a long track record of dividend growth.

  • News Sentiment

    Pro-Dex has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Pro-Dex this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Pro-Dex insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    45.90% of the stock of Pro-Dex is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    15.28% of the stock of Pro-Dex is held by institutions.

  • Read more about Pro-Dex's insider trading history.
Receive PDEX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pro-Dex and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PDEX Stock News Headlines

Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
Pro-Dex Valuation Is Attractive Despite Customer Risk
See More Headlines

PDEX Stock Analysis - Frequently Asked Questions

Pro-Dex's stock was trading at $38.48 on January 1st, 2026. Since then, PDEX stock has increased by 49.1% and is now trading at $57.3760.

Pro-Dex, Inc. (NASDAQ:PDEX) announced its quarterly earnings data on Thursday, April, 30th. The medical instruments supplier reported $1.20 EPS for the quarter, beating the consensus estimate of $0.62 by $0.58. The medical instruments supplier had revenue of $19.95 million for the quarter, compared to the consensus estimate of $17.90 million. Pro-Dex had a net margin of 16.08% and a trailing twelve-month return on equity of 22.78%.

Top institutional investors of Pro-Dex include Dimensional Fund Advisors LP (1.78%), Bank of New York Mellon Corp (0.34%), Morgan Dempsey Capital Management LLC (0.18%) and Ritholtz Wealth Management (0.17%). Insiders that own company stock include Alisha Charlton and Angelita Rebamontan Domingo.
View institutional ownership trends
.

Shares of PDEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pro-Dex investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), ServiceNow (NOW), Arista Networks (ANET) and Jabil (JBL).

Company Calendar

Last Earnings
4/30/2026
Today
5/11/2026
Fiscal Year End
6/30/2026
Next Earnings (Estimated)
7/08/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED/DENTAL - SUPP
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:PDEX
CIK
788920
Employees
140
Year Founded
1975

Price Target and Rating

High Price Target
$56.00
Low Price Target
$56.00
Potential Upside/Downside
-0.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.62
Trailing P/E Ratio
15.61
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$8.98 million
Net Margins
16.08%
Pretax Margin
21.56%
Return on Equity
22.78%
Return on Assets
14.30%

Debt

Debt-to-Equity Ratio
0.32
Current Ratio
3.67
Quick Ratio
2.14

Sales & Book Value

Annual Sales
$74.64 million
Price / Sales
2.42
Cash Flow
$2.99 per share
Price / Cash Flow
18.90
Book Value
$11.23 per share
Price / Book
5.03

Miscellaneous

Outstanding Shares
3,193,000
Free Float
1,727,000
Market Cap
$180.44 million
Optionable
Not Optionable
Beta
-0.12

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:PDEX) was last updated on 5/11/2026 by MarketBeat.com Staff.
From Our Partners